Table 6.

Per person day rate of Adverse Events (AEs) during first 10 and 28 days with estimates (95% CI) and p-value based on negative binomial regression with a likelihood ratio test. AEs were assessed by a blinded investigator, and expected AEs for COVID-19 and losartan are listed and analyzed below. For potentially related AEs to the intervention, the likelihood (unrelated, unlikely, possibly, probably, or definitely) was assessed based on the blinded investigator's judgment.

	Losartan (n = 58)	Placebo (n = 59)	P-value
First 10 Days Per-Person Per-Day AE Rates
Expected Covid-19	0.138 (0.1,0.189)	0.181 (0.134,0.244)	0.2137
Expected Losartan (Any Relatedness)	0.064 (0.046,0.089)	0.062 (0.045,0.086)	0.8776
Expected Losartan (Unlikely or More Related)	0.05 (0.034,0.074)	0.041 (0.027,0.063)	0.4913
Expected Losartan (Possibly or More Related)	0.012 (0.006,0.026)	0.012 (0.006,0.026)	0.9871
Expected Losartan (Probably Related)	0 (0,Inf)	0.002 (0,0.012)	0.2405
First 28 Days Per-Person Per-Day AE Rates
Expected Covid-19	0.058 (0.044,0.078)	0.077 (0.059,0.1)	0.1711
Expected Losartan (Any Relatedness)	0.027 (0.02,0.037)	0.028 (0.021,0.038)	0.8688
Expected Losartan (Unlikely or More Related)	0.022 (0.015,0.033)	0.021 (0.014,0.031)	0.8048
Expected Losartan (Possibly or More Related)	0.005 (0.002,0.01)	0.005 (0.002,0.01)	0.9814
Expected Losartan (Probably Related)	0 (0,Inf)	0.001 (0,0.005)	0.2369